Increased seizure threshold and severity in young transgenic CRND8 mice

被引:87
作者
Del Vecchio, RA
Gold, LH
Novick, SJ
Wong, G
Hyde, LA
机构
[1] Schering Plough Res Inst, CNS Biol Res, Kenilworth, NJ 07033 USA
[2] Pfizer Global R&D, Ann Arbor Labs, Ann Arbor, MI 48105 USA
[3] GlaxoSmith Kline, Res Triangle Pk, NC 27709 USA
[4] ALS Therapy Dev Fdn, Cambridge, MA 02142 USA
关键词
seizures; CRND8; mouse; Alzheimer's disease; seizure threshold; beta-amyloid;
D O I
10.1016/j.neulet.2004.05.107
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Reports suggest that Alzheimer's disease (AD) patients show a high life-time prevalence of seizure-like disorders. The transgenic CRND8 (TgCRDN8) is a mouse model of AD-like amyloid pathogenesis that expresses a double-mutant form of human amyloid precursor protein 695 (K670N/M671L and V717F). We have previously reported that post-plaque TgCRND8 mice exhibited a lower threshold to seizure with a more severe seizure type when challenged with pentylenetetrazole (PTZ) intravenously. Here, we now report that pre-plaque TgCRND8 mice also demonstrate an increased sensitivity to PTZ-induced seizures with a more severe seizure type over age-matched littermate controls. A lower threshold and more severe seizure type in TgCRND8 mice prior to and after plaque deposition suggest that this genotype difference may be due to beta-amyloid (Abeta) toxicity rather than plaque formation. Thus, the TgCRND8 mice are not only a model for Abeta production and plaque deposition, but may also be useful for AD associated seizure. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:164 / 167
页数:4
相关论文
共 23 条
[1]   Alzheimer's disease underlies some cases of complex partial status epilepticus - Clinical, radiologic, EEG, and pathologic correlations [J].
Armon, C ;
Peterson, GW ;
Liwnicz, BH .
JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2000, 17 (05) :511-518
[2]   Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695 [J].
Chishti, MA ;
Yang, DS ;
Janus, C ;
Phinney, AL ;
Horne, P ;
Pearson, J ;
Strome, R ;
Zuker, N ;
Loukides, J ;
French, J ;
Turner, S ;
Lozza, G ;
Grilli, M ;
Kunicki, S ;
Morissette, C ;
Paquette, J ;
Gervais, F ;
Bergeron, C ;
Fraser, PE ;
Carlson, GA ;
St George-Hyslop, P ;
Westaway, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (24) :21562-21570
[3]   MUTATION OF THE BETA-AMYLOID PRECURSOR PROTEIN IN FAMILIAL ALZHEIMERS-DISEASE INCREASES BETA-PROTEIN PRODUCTION [J].
CITRON, M ;
OLTERSDORF, T ;
HAASS, C ;
MCCONLOGUE, L ;
HUNG, AY ;
SEUBERT, P ;
VIGOPELFREY, C ;
LIEBERBURG, I ;
SELKOE, DJ .
NATURE, 1992, 360 (6405) :672-674
[4]   Mapping loci for pentylenetetrazol-induced seizure susceptibility in mice [J].
Ferraro, TN ;
Golden, GT ;
Smith, GG ;
St Jean, P ;
Schork, NJ ;
Mulholland, N ;
Ballas, C ;
Schill, J ;
Buono, RJ ;
Berrettini, WH .
JOURNAL OF NEUROSCIENCE, 1999, 19 (16) :6733-6739
[5]   SEIZURES AND MYOCLONUS IN PATIENTS WITH ALZHEIMERS-DISEASE [J].
HAUSER, WA ;
MORRIS, ML ;
HESTON, LL ;
ANDERSON, VE .
NEUROLOGY, 1986, 36 (09) :1226-1230
[6]  
HINT HC, 1958, ACTA PHARMACOL TOX, V14, P153
[7]  
Huang RQ, 2001, J PHARMACOL EXP THER, V298, P986
[8]   Long-term potentiation is increased in the CA1 area of the hippocampus of APPswe/ind CRND8 mice [J].
Jolas, T ;
Zhang, XS ;
Zhang, Q ;
Wong, G ;
Del Vecchio, R ;
Gold, L ;
Priestley, T .
NEUROBIOLOGY OF DISEASE, 2002, 11 (03) :394-409
[9]   APP processing and synaptic function [J].
Kamenetz, F ;
Tomita, T ;
Hsieh, H ;
Seabrook, G ;
Borchelt, D ;
Iwatsubo, T ;
Sisodia, S ;
Malinow, R .
NEURON, 2003, 37 (06) :925-937
[10]   GENETIC CORRELATIONS AMONG INBRED STRAIN SENSITIVITIES TO CONVULSIONS INDUCED BY 9 CONVULSANT DRUGS [J].
KOSOBUD, AE ;
CRABBE, JC .
BRAIN RESEARCH, 1990, 526 (01) :8-16